Novel Insight into the Diagnosis and Management of Crohn’s Disease

Dear Colleagues,

In recent years, huge progress has been made in both the diagnosis and monitoring of Crohn’s disease. Non-invasive, patient-friendly, and remote monitoring techniques such as capsule endoscopy, intestinal ultrasound, and home-based fecal calprotectin are gaining increased acceptance, replacing more traditional and invasive monitoring techniques. The ongoing COVID-19 pandemic has caused significant restrictions on patient mobility, which along with reluctance to visit medical facilities further enhances this paradigm shift. Novel and more ambitious treatment goals such as transmural healing and histological healing are being evaluated in clinical trials and observational studies. Although these treatment goals are not yet considered as major therapeutic goals, they are routinely included in clinical trials as secondary endpoints.

The therapeutic armamentarium in IBD has been rapidly expanding in the last decade. In addition to monoclonal antibodies targeting novel mechanisms (leukocyte adhesion, JAK/STAT pathway, interleukin 12 and 23), biosimilar therapies are changing the biological therapy market, causing significant cost reductions for well-established molecules such as infliximab and adalimumab. In addition, there is increasing evidence to support subcutaneous use of previously IV-only medications (infliximab and vedolizumab), this trend being particularly important during the COVID-19 era.

The current Special Issue will focus on novel diagnostic and therapeutic strategies in CD, including but not limited to novel biomarkers, remote monitoring of disease activity, novel drug combinations, and therapeutic targets.

Prof. Dr. Uri Kopylov
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.